MEDS (DataMEDS AI) 3-Year ROIIC % : 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DataMEDS AI 3-Year ROIIC %?

DataMEDS AI MEDS -3.35% 3-Year ROIIC % is 0.00 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 113 Medical Distribution companies, DataMEDS AI ranks worse than 884954.87% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. DataMEDS AI does not have enough data to calculate 3-Year ROIIC %.


DataMEDS AI  (NAS:MEDS) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


DataMEDS AI 3-Year ROIIC % Related Terms


DataMEDS AI 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for DataMEDS AI's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DataMEDS AI 3-Year ROIIC % Chart

DataMEDS AI Annual Data
Trend Dec22 Dec23 Dec24 Dec25
3-Year ROIIC %
0.00 0.00 0.00 0.00

DataMEDS AI Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEDS vs HEWA, BLMH, PMHS: 3-Year ROIIC % Comparison

For the Medical Distribution subindustry, DataMEDS AI's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DataMEDS AI 3-Year ROIIC % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, DataMEDS AI's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where DataMEDS AI's 3-Year ROIIC % falls into.



DataMEDS AI 3-Year ROIIC % Calculation

DataMEDS AI's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -81.195 (Dec. 2025) - -3.423 (Dec. 2022) )/( 44.357 (Dec. 2025) - 0 (Dec. 2022) )
=-77.772/
=N/A%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of 0.00 mean?
DataMEDS AI (MEDS) has a 3-Year ROIIC % of 0.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #999999 out of 113 companies in the Medical Distribution industry.
Is DataMEDS AI's 3-Year ROIIC % too high?
DataMEDS AI's current 3-Year ROIIC % is 0.00. Based on the distribution chart, DataMEDS AI ranks #999999 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's 3-Year ROIIC % compare to HEWA and BLMH?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #999999 out of 113 companies for 3-Year ROIIC %. This places DataMEDS AI in the lower half of its industry. The industry median 3-Year ROIIC % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.20, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DataMEDS AI Business Description

Address 3000 Bayport Drive, Suite 950, Tampa, FL, USA, 33607
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.